Crohn Disease

Small, open-label study shows potential use of antibiotic

Published in TB and Outbreaks Week, June 14th, 2005

A small, open-label study conducted by physicians at New York-Presbyterian Hospital/Weill Cornell Medical Center suggests that there may be a new application for the novel antibiotic rifaximin in treating patients who suffer from severe Crohn disease and who have not responded to all other available medications for the disease.

The study was conducted by Dr. Ellen Scherl, assistant professor of medicine at Weill Medical College of Cornell University, and colleagues.

The physicians are encouraged by the unexpected results of rifaximin, which was FDA-approved last year for traveler's diarrhea. But, they cautioned, these preliminary findings still...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2005-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry